SCHEMBL597405

SCHEMBL597405

C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cccc(C#N)c3)n[nH]c2C1(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PRKCB P05771 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL597140 0.90 PRKCB (1.00) PRKCB
SCHEMBL14038609 0.89 PRKCB (1.00) PRKCB
SCHEMBL598501 0.89 PRKCB (1.00) PRKCB
SCHEMBL597116 0.89 PRKCB (1.00) PRKCB
SCHEMBL597658 0.89 PRKCB (1.00) PRKCB
SCHEMBL596373 0.87 PRKCB (1.00) PRKCB
SCHEMBL596353 0.87 PRKCB (0.85) PRKCB
SCHEMBL602141 0.87 PRKCB (1.00) PRKCB
SCHEMBL596914 0.85 PRKCB (1.00) PRKCB
SCHEMBL596893 0.84 PRKCB (0.86) PRKCB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999981-B2 3-amido-pyrrolo[3,4-C]pyrazole-5(1H, 4H,6H) carbaldehyde derivatives PFIZER INC. (US) 2015-04-07 US claimed
US-20230099852-A1 TREATMENT OF AUTOIMMUNE DISEASE MINGSIGHT PHARMACEUTICALS INC (US) 2023-03-30 US disclosed
CN-115381832-A Treatment of cancer 深圳明赛瑞霖药业有限公司 2022-11-25 CN disclosed
US-20220202814-A1 TREATMENT OF CANCER MINGSIGHT PHARMACEUTICALS, INC. 2022-06-30 US disclosed
US-20210401837-A1 TREATMENT OF CANCER MINGSIGHT PHARMACEUTICALS, INC. 2021-12-30 US disclosed
US-11154555-B2 Treatment of cancer MINGSIGHT PHARMACEUTICALS, INC. (US) 2021-10-26 US disclosed
EP-3145931-B1 TREATMENT OF AUTOIMMUNE DISEASE MINGSIGHT PHARMACEUTICALS INC (US) 2021-03-31 EP disclosed
CN-111568905-A Treatment of autoimmune diseases 深圳明赛瑞霖药业有限公司 2020-08-25 CN disclosed
CN-106727582-B Treatment of autoimmune diseases 深圳明赛瑞霖药业有限公司 2020-06-12 CN disclosed
US-20190216809-A1 TREATMENT OF CANCER MINGSIGHT PHARMACEUTICALS, INC. (US) 2019-07-18 US disclosed
US-8999981-B2 3-amido-pyrrolo[3,4-C]pyrazole-5(1H, 4H,6H) carbaldehyde derivatives PFIZER INC. (US) 2015-04-07 US disclosed
US-20120108588-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES PFIZER, INC. (US) 2012-05-03 US disclosed
US-20120108588-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES PFIZER, INC. (US) 2012-05-03 US disclosed
US-8114871-B2 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives PFIZER INC. (US) 2012-02-14 US disclosed
US-8114871-B2 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives PFIZER INC. (US) 2012-02-14 US disclosed
US-8114871-B2 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives PFIZER INC. (US) 2012-02-14 US disclosed
US-20100249128-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2010-09-30 US disclosed
US-20100249128-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2010-09-30 US disclosed
US-20100249128-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2010-09-30 US disclosed
WO-2008125945-A2 3-AMIDO-PYRROLO [3, 4-C] PYRAZOLE-5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE C PFIZER INC. (US) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202814-A1 TREATMENT OF CANCER PRKACB, PRKDC, PRKCH PRKCB 4/4885
US-20210401837-A1 TREATMENT OF CANCER PRKACB, PRKDC, PRKCH PRKCB 4/4885
US-20100249128-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES INSR, IAPP, PYCR1 PRKCB 2011/4885
US-20120108588-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES INSR, IAPP, PYCR1 PRKCB 2011/4885
US-20230099852-A1 TREATMENT OF AUTOIMMUNE DISEASE PRKACB, PRKACG, PRKACA PRKCB 8/4885
US-20190216809-A1 TREATMENT OF CANCER PRKCH, PRKCB, PRKCG PRKCB 2/4885
US-11154555-B2 Treatment of cancer PRKCH, PRKCB, PRKCG PRKCB 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.